This Week in General Medicine — Jul 27, 2026

Welcome to This Week in General Medicine. This week we're covering 4 notable papers spanning diagnostic artificial intelligence, biomarker validation in metabolic liver disease, targeted therapeutics in dermatology, and psychometric measurement in primary care. Let's dive in.

Beginning with advancements in diagnostic technology and chronic disease assessment, two new studies explore how we detect and stage complex conditions. In Nature Medicine, Jia and colleagues evaluated Retina4IRD, an artificial intelligence-based clinician decision support system designed to predict 17 genotype categories from retinal images using a Vision Transformer model [1]. In a randomized controlled trial involving 350 participants with suspected inherited retinal diseases, specialists aided by the tool achieved a significantly higher top-5 genetic accuracy of 88.5% compared to 67.3% in the specialist-only control arm [1]. Furthermore, downstream management scores were significantly higher in the AI-assisted group, suggesting the tool effectively integrates into clinical workflows prior to genetic testing [1].

Turning to metabolic dysfunction-associated steatotic liver disease, also featured in Nature Medicine, Pavlides and colleagues conducted a prospective multicenter study to evaluate noninvasive imaging and serum diagnostic biomarkers [2]. Assessing 357 participants, the investigators found that for diagnosing cirrhosis, several modalities exceeded minimum acceptable performance criteria, including magnetic resonance elastography with an area under the curve of 0.91, vibration-controlled transient elastography at 0.87, and composite scores such as Agile 3+ at 0.89 and Agile 4 at 0.88 [2]. While serum biomarkers like NIS2+ tended to outperform imaging for identifying at-risk metabolic dysfunction-associated steatohepatitis, imaging modalities and composite scores showed excellent accuracy for staging advanced fibrosis and cirrhosis [2].

In therapeutics for chronic inflammatory conditions, Porter and colleagues published findings from the STOP-HS1 and STOP-HS2 phase 3 trials in Nature Medicine, investigating povorcitinib, an oral selective Janus kinase 1 inhibitor, in moderate to severe hidradenitis suppurativa [3]. Across both identically designed trials involving over 600 patients each, once-daily povorcitinib at both 45-milligram and 75-milligram doses met the primary endpoint, with approximately 40 to 42 percent of patients achieving at least a 50 percent decrease in abscess and inflammatory nodule count at week 12, compared to 29 to 30 percent in the placebo groups [3]. Serious adverse events were low across all arms through week 12, demonstrating significant clinical improvement and a favorable safety profile [3].

Finally, addressing measurement precision in mental health screening, Wang and colleagues performed an individual participant data meta-analysis published in the BMJ to estimate the minimal detectable change for the Patient Health Questionnaire instruments [4]. Analyzing data from over 42,000 participants across 94 studies for the PHQ-9 and PHQ-8, and over 44,000 participants for the PHQ-2, the pooled 95 percent minimal detectable change was 5.72 points for the PHQ-9, 5.51 points for the PHQ-8, and 2.26 points for the PHQ-2 [4]. The threshold for the PHQ-9 increased in inpatient settings and with higher proportions of major depression, indicating that clinicians in general practice should look for a six-point change to confirm true clinical movement beyond measurement error [4].

If you only have time for one paper this week, make it the trial by Jia and colleagues on the artificial intelligence-based decision support system for inherited retinal diseases [1]. It provides actionable evidence that artificial intelligence integration can directly improve specialist diagnostic accuracy and management decisions prior to costly genetic testing [1].

Here are the key takeaways from this week in General Medicine. Artificial intelligence-assisted screening significantly improves top-5 genetic diagnostic accuracy and downstream management for inherited retinal diseases [1]. Magnetic resonance elastography and composite scores like Agile 3+ demonstrate excellent diagnostic performance for staging advanced fibrosis and cirrhosis in metabolic liver disease [2]. Oral povorcitinib achieves significant clinical response rates in moderate to severe hidradenitis suppurativa with a manageable safety profile [3]. A change of six points on the Patient Health Questionnaire-9 is required in general practice to ensure score variations exceed measurement error [4].

That's your roundup for This Week in General Medicine. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week. One more note before you go: only 4 new papers of note met the bar since the last update — a quieter stretch for new literature. Still worth revisiting from recent updates: What to Know About the First CKM Syndrome Guidelines, in JAMA; and Global Cardiology Groups Issue New Universal Definition of Heart Failure, in JAMA.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And for audio briefings on your own clinical questions and papers, visit audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.